Safety of Insulin Glargine Use in Pregnancy: A Systematic Review and Meta-Analysis
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: The prevalence of diabetes in women of childbearing age is increasing. As such, the number of pregnancies complicated by diabetes will inevitably increase. New insulin analogues such as the long-acting analogue Insulin glargine may represent beneficial treatment options in pregnancy by ensuring that patients achieve excellent glycemic control without risk of maternal hypoglycemia. Objective: To determine the fetal safety of insulin glargine use in the treatment of diabetes in pregnancy compared with NPH insulin therapy. Methods: A systematic review and meta-analysis was performed of all original human studies that reported neonatal outcomes among women with pregestational or gestational diabetes who were managed with either insulin glargine or NPH insulin during pregnancy. A systematic literature search was conducted using MEDLINE, EMBASE, CINAHL, the Cochrane Central Register for Controlled Trials database, and Web of Science from 1980 to June 1, 2010. Outcomes included large size for gestational age, macrosomia, neonatal hypoglycemia, neonatal intensive care unit admissions, birth trauma, congenital anomalies, preterm delivery, perinatal mortality, respiratory distress, and hyperbilirubinemia. Relative risk ratios and weighted mean differences were computed with 95% confidence intervals. Results: Eight studies reporting on a total of 702 women with pregestational or gestational diabetes in pregnancy treated with either insulin glargine (n = 331) or NPH insulin (n = 371) met the inclusion criteria. There were no statistically significant differences in the occurrence of fetal outcomes studied with the use of insulin glargine compared to NPH insulin. Conclusions: No evidence has been documented for increased adverse fetal outcomes with the use of insulin glargine in pregnancy compared to the use of NPH insulin. These results increase the choices for women requiring basal insulin therapy in pregnancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing heterogeneity in meta-analysis: Q statistic or I² index?
Huedo-Medina, T. B., Sánchez-Meca, J., Marín-Martínez, F., & Botella, J. (2006) · Psychological Methods · doi:10.1037/1082-989x.11.2.193 · Cited by 4,256
Vandenbroucke, J. P., von Elm, E., Altman, D. G., Gøtzsche, P. C., Mulrow, C. D., Pocock, S. J., Poole, C., Schlesselman, J. J., & Egger, M. (2007) · Epidemiology · doi:10.1097/ede.0b013e3181577511 · Cited by 2,779
Kurtzhals, P., Schäffer, L., Sørensen, A., Kristensen, C., Jonassen, I., Schmid, C., & Trüb, T. (2000) · Diabetes · doi:10.2337/diabetes.49.6.999 · Cited by 739
Insulin Glargine Safety in Pregnancy
Pollex, E. K., Feig, D. S., Lubetsky, A., Yip, P. M., & Koren, G. (2010) · Diabetes Care · doi:10.2337/dc09-1045 · Cited by 104
Self-citationUse of insulin glargine during pregnancy
PÖYHÖNEN‐ALHO, M., RÖNNEMAA, T., SALTEVO, J., EKBLAD, U., & KAAJA, R. J. (2007) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.1080/00016340701515282 · Cited by 52
Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study
IMBERGAMO, M., AMATO, M., SCIORTINO, G., GAMBINA, M., ACCIDENTI, M., CRISCIMANNA, A., GIORDANO, C., & GALLUZZO, A. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.013 · Cited by 46
Victor Fang, Y. M., Mackeen, D., Egan, J. F. X., & Zelop, C. M. (2009) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767050802638170 · Cited by 45
Insulin glargine versus neutral protamine Hagedorn insulin for treatment of diabetes in pregnancy
Smith, J., Manuck, T., White, J., & Merrill, D. (2009) · American Journal of Perinatology · doi:10.1055/s-0028-1095181 · Cited by 22
Cited by
Hod, M., Kapur, A., Sacks, D. A., Hadar, E., Agarwal, M., Di Renzo, G. C., Roura, L. C., McIntyre, H. D., Morris, J. L., & Divakar, H. (2015) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(15)30033-3 · Cited by 767
15. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s015 · Cited by 504
Thompson, D., Berger, H., Feig, D., Gagnon, R., Kader, T., Keely, E., Kozak, S., Ryan, E., Sermer, M., & Vinokuroff, C. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.044 · Cited by 377
Self-citationFeig, D. S., Berger, H., Donovan, L., Godbout, A., Kader, T., Keely, E., & Sanghera, R. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.038 · Cited by 344
Self-citation15. Management of Diabetes in Pregnancy:Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s015 · Cited by 284
Metadata
- Authors
- Pollex, E., Moretti, M. E., Koren, G., & Feig, D. S.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2011-01
- Volume
- 45
- Issue
- 1
- Pages
- 9-16
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2118839320
- Cited by
- 116
- References
- 8
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.